Nanoformulation of a novel potent ebselen analog for treatment of vulvovaginal candidiasis.

Vulvovaginal candidiasis is primarily caused by (). Here, a novel organoselenium compound (G20) was synthesized and evaluated for anti- activity. Growth-inhibition studies and medium acidification assays to assess the inhibition of the yeast plasma membrane H-ATPase (Pma1p) were carried out using G20. A self-nanoemulsifying formulation (SNEP) of G20 was prepared and evaluated for antimycotic activity in a mouse model. G20 inhibited the growth of through a mechanism that, at least in part, involves the inhibition of Pma1p. The G20-SNEP formulation significantly reduced vaginal colonization and vaginal inflammation relative to yeast-infected but untreated control mice. G20-SNEP exhibits potent antimycotic activity in a mouse model of vulvovaginal candidiasis.